Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ben Tre Pharmaceutical JSCSTC:DBT +1.59%13 3-1 Month Momentum % is 14.80% as of Jul. 28, 2026. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,024 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks better than 84.67% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-28), Ben Tre Pharmaceutical JSC's 3-1 Month Momentum % is 14.80%.
The industry rank for Ben Tre Pharmaceutical JSC's 3-1 Month Momentum % or its related term are showing as below:
STC:DBT's 3-1 Month Momentum % is ranked better than 84.67% of 1024
companies
in the Drug Manufacturers industry
Industry Median: -8.205
vs STC:DBT: 14.80
Ben Tre Pharmaceutical JSC (STC:DBT) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ben Tre Pharmaceutical JSC 3-1 Month Momentum % Related Terms
STC:DBT vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ben Tre Pharmaceutical JSC 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ben Tre Pharmaceutical JSC's 3-1 Month Momentum % falls into.
Ben Tre Pharmaceutical JSC (STC:DBT) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Tre Pharmaceutical JSC (STC:DBT) has a 3-1 Month Momentum % of 14.80% as of Jul. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #157 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Ben Tre Pharmaceutical JSC's 3-1 Month Momentum % too high?
Ben Tre Pharmaceutical JSC's current 3-1 Month Momentum % is 14.80%. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #157 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #157 out of 1024 companies for 3-1 Month Momentum %. This places Ben Tre Pharmaceutical JSC in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ben Tre Pharmaceutical JSC and its competitors. Ben Tre Pharmaceutical JSC's current 3-1 Month Momentum % is 14.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current 3-1 Month Momentum % of 14.80%. The current 3-1 Month Momentum % is 14.80%. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current 3-1 Month Momentum % is 14.80% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score
Get the complete analysis for STC:DBT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBT has been successfully added to your 
